Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

SmithOnStocks Top Stock Picks for 2017, January 3, 2017

Purpose of this Report

I last summarized my stock recommendations in a September 12, 2016 report. There has been little change…
Read more…

Windtree Therapeutics (WINT, $2.50): Critical Aerosurf Phase 2b Trial Completion is Delayed; Can the Company Raise the Capital Needed to Complete the Trial

Overview

Windtree held a conference call on October 25 to update investors on the status of the phase 2a trial of…
Read more…

Windtree Therapeutics: Key Points from Conference Call on 1Q, 2016 Results (WINT, $2.04)

Investment Thesis

The current market valuation of Windtree is only $16 million. This seems extremely low for a Company that…
Read more…

Discovery Laboratories: Clinical Trial Data over Next Year Could Validate the Promise of Aerosurf (DSCO, Buy, $1.60)

Investment Overview

The Stock Market Has Written off Aerosurf

The current stock market valuation for Discovery Laboratories of $13 million (8 million…
Read more…

Discovery Laboratories: New CEO and Update on Aerosurf (DSCO, $2.26)

Upcoming Key Events

There are two very important events in the next year. The first is reporting of results in a…
Read more…

Discovery Laboratories: Results for Aerosurf in Phase 2a Trial are Encouraging; Why Then Did the Stock Crash? (DSCO, Buy, $0.30)

Introduction

This report discusses the results of Discovery Laboratory’s first in human, phase 2a trial of Aerosurf. In writing this report,…
Read more…

Discovery Laboratories: Update from the 2Q, 2015 Conference Call Provides Timelines for Important Aerosurf Phase 2 Trials (DSCO, Buy, $0.47)

Key Points

Phase 2 trials are enrolling rapidly.
Topline results from a trial involving babies of 29 to 34 weeks gestational age…
Read more…

Comments on Agenus, ImmunoCellular, Discovery Laboratories, Neuralstem, Kite and Juno

SmithOnStocks Mailbox
 Comments on Agenus, ImmunoCellular, Discovery Laboratories, Neuralstem, Kite and Juno
About the Mailbox:

My mailbox comments are brief notes on stocks…
Read more…

Discovery Laboratories: What I Intend to Do in the Aftermath of a Disastrous Stock Offering (DSCO, Buy, $0.54)

Quick Summary
Discovery Laboratories has just completed a stock offering that was done at distressed prices. This was a disaster for…
Read more…

Discovery Laboratories: An Analysis of Phase 2a Results for Aerosurf and What to do with the Stock (DSCO, $0.81, for paid subscribers)

Glossary of Important Definitions

For those of you who are not familiar with terms used in neonatology, I am starting this…
Read more…

Discovery Laboratories: Focus is Totally on Aerosurf Development (DSCO, $1.43, Hold)

Investment Thesis

During the conference call on March 16, 2015 discussing 4Q, 2014 results, management announced that it had decided to…
Read more…

Discovery Laboratories: Delay in Completion of Aerosurf Phase 2a Trial and Continued Disappointing Sales of Surfaxin Weigh on the Stock (DSCO, $1.53, Hold)

Phase 2a Aerosurf trial completion has been pushed back to 1Q, 2015 from 4Q, 2014.
All important topline results from Aerosurf…
Read more…

Discovery Laboratories Has Formed an Important Collaboration with Battelle to Develop Aerosurf (DSCO, Buy, $1.69)

This agreement partners Discovery with a world class medical device developer and meaningfully de-risks development of Aerosurf.
It also gives meaningful…
Read more…

Discovery Laboratories: My Current Thinking on the Surfaxin Launch and Aerosurf Phase 2 Trials (DSCO, Buy/Hold, $1.62)

Investment Thesis

At the time of launch of Surfaxin on November 8, 2013 Discovery Laboratory’s (DSCO) stock was selling at $2.00.…
Read more…

Discovery Laboratories: A Look at the Surfaxin Launch and the Phase 2a Trial of Aerosurf (DSCO, Buy, $1.79, free content)

Launch of Surfaxin

The launch of Surfaxin has begun and initial results were below expectations causing the Company a few months…
Read more…

Discovery Laboratories: An Update on the Surfaxin Launch and the Phase 2 Clinical Trial Program for Aerosurf (DSCO, Buy, $1.72)

Introduction and Overview

This note updates recent progress of the company along with my detailed investment outlook which I break into…
Read more…

Discovery Laboratories: An Asymmetric Opportunity (DSCO, $2.07)

I have just published the first of a series of reports on Discovery Laboratories.
Instead of publishing an extensive report (which…
Read more…

Discovery Laboratories (DSCO, $2.07): An Asymmetric Opportunity

 
Purpose of This Report
This is the first of a series of reports on Discovery Laboratories. Instead of publishing an extensive…
Read more…

Discovery Laboratories: Removal of Financing Overhang Is a Catalyst for the Stock (DSCO, $2.17)

Investment Thesis
I believe that the recent stock offering by Discovery Laboratories (DSCO) removes the financing overhang that has been holding…
Read more…

Discovery Laboratories: What the Marketing Approval of Surfaxin Could Mean to the Stock (DSCO, $2.72)

Surfaxin is Finally Cleared for Commercialization in the US
The long saga for Discovery Laboratories (DSCO) that began with the first…
Read more…

Discovery Laboratories: Still Another Delay in the Surfaxin Launch (DSCO, $2.00)

Overview
Discovery Laboratories just announced still another delay in the launch of Surfaxin. The Company received five Complete Response letters dating…
Read more…

Discovery Laboratories: The Surfaxin Launch and Beyond (DSCO, $2.38)

Investment Thesis
We are now nearing the long awaited launch of Surfaxin. During the recent conference call on results for 4Q,…
Read more…

Discovery Laboratories: Innovative Financing is a Catalyst to Buy the Stock (DSCO, $2.16)

Investment Perspective
Discovery's (DSCO) stock has languished since it announced before the opening on October 24, 2012 that it was delaying…
Read more…

Discovery Laboratories Announces Changing of the Guard (DSCO, $2.21)

New Board and New CEO
There has been a significant leadership change at Discovery Laboratories (DSCO) which has appointed a new…
Read more…

Discovery Laboratories: Disappointment with the Delay in the Surfaxin Launch Has Created a Buying Opportunity (DSCO, $2.24)

Introduction
I had the opportunity to meet with the management of Discovery Laboratories (DSCO) recently and focused on several issues:


Read more…

Discovery Laboratories: The Street Is Getting on Board With Me

My Recent History on Discovery Laboratories

On February 22, 2012, I initiated coverage of Discover Laboratories with a Buy and at…
Read more…

Discovery Laboratories: Surfaxin Is Superior to Animal Surfactants (DSCO, $2.74)

Purpose of Report
Discovery Laboratories (DSCO) held a quarterly conference call on May 3 to update investors on the pending launch…
Read more…

Discovery Laboratories (DSCO): An Update and Buy Re-iteration

I have just published a new report on Discovery Laboratories; this emerging company has two products approved for U.S. marketing…
Read more…

Equity Offering Provides Discovery Laboratories Much Needed Financial Strength (DSCO, $2.81)

Report Summary
With a number of cash infusions from a public offering, an ATM drawdown and warrant exercises, Discovery Laboratories (DSCO)…
Read more…

Surfaxin Should Be Approved on its March 6th PDUFA Date (DSCO, $2.82)

Investment Thesis and Valuation
The transformation of a biotechnology company from development stage to commercial can be the catalyst for a…
Read more…